EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 270 filers reported holding EXELIXIS INC in Q3 2017. The put-call ratio across all filers is 0.68 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $2,009,919 | +224.6% | 89,449 | +242.8% | 0.00% | +200.0% |
Q1 2024 | $619,282 | -41.8% | 26,097 | -41.2% | 0.00% | -50.0% |
Q4 2023 | $1,064,316 | -27.0% | 44,365 | -33.5% | 0.00% | -50.0% |
Q3 2023 | $1,457,570 | +39.5% | 66,708 | +22.0% | 0.00% | +33.3% |
Q2 2023 | $1,045,107 | +192.2% | 54,689 | +145.3% | 0.00% | +200.0% |
Q4 2022 | $357,676 | -80.2% | 22,299 | -72.0% | 0.00% | -87.5% |
Q1 2022 | $1,805,000 | -1.8% | 79,619 | -20.8% | 0.01% | +60.0% |
Q4 2021 | $1,838,000 | -75.8% | 100,570 | -72.0% | 0.01% | -77.3% |
Q3 2021 | $7,604,000 | +54.0% | 359,712 | +32.7% | 0.02% | +15.8% |
Q2 2021 | $4,939,000 | -39.4% | 271,077 | -24.8% | 0.02% | -60.4% |
Q1 2021 | $8,146,000 | +301.9% | 360,602 | +257.0% | 0.05% | +220.0% |
Q4 2020 | $2,027,000 | +40.5% | 101,007 | +71.1% | 0.02% | -21.1% |
Q3 2020 | $1,443,000 | -84.6% | 59,027 | -85.0% | 0.02% | -87.4% |
Q2 2020 | $9,354,000 | +219.5% | 394,024 | +131.7% | 0.15% | +101.3% |
Q1 2020 | $2,928,000 | -76.7% | 170,044 | -76.1% | 0.08% | 0.0% |
Q4 2019 | $12,542,000 | +131.9% | 711,829 | +132.8% | 0.08% | +56.2% |
Q3 2019 | $5,408,000 | +127.3% | 305,778 | +174.7% | 0.05% | +108.7% |
Q2 2019 | $2,379,000 | +56.3% | 111,332 | +43.9% | 0.02% | +27.8% |
Q4 2018 | $1,522,000 | -8.4% | 77,356 | -17.5% | 0.02% | -10.0% |
Q3 2018 | $1,661,000 | -81.6% | 93,748 | -77.6% | 0.02% | -83.2% |
Q2 2018 | $9,017,000 | +218.7% | 419,022 | +228.1% | 0.12% | +164.4% |
Q1 2018 | $2,829,000 | -65.9% | 127,725 | -53.2% | 0.04% | -69.0% |
Q4 2017 | $8,299,000 | +42.4% | 273,002 | +13.5% | 0.14% | +29.5% |
Q3 2017 | $5,827,000 | -30.3% | 240,472 | -29.1% | 0.11% | -31.7% |
Q2 2017 | $8,358,000 | +358.7% | 339,333 | +303.6% | 0.16% | +228.0% |
Q1 2017 | $1,822,000 | +114.1% | 84,083 | +47.4% | 0.05% | +42.9% |
Q4 2016 | $851,000 | +34.7% | 57,046 | +15.5% | 0.04% | -16.7% |
Q3 2016 | $632,000 | +267.4% | 49,400 | +124.5% | 0.04% | +281.8% |
Q2 2016 | $172,000 | -21.1% | 22,000 | -59.6% | 0.01% | -35.3% |
Q1 2016 | $218,000 | -78.0% | 54,513 | -69.0% | 0.02% | -84.4% |
Q4 2015 | $992,000 | – | 175,900 | – | 0.11% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |